The field of adeno-associated virus (AAV) gene therapy has progressed rapidly over the past decade, with the advent of novel capsid serotype and organ-specific promoters, and an increasing understanding of the immune response to AAV administration. In particular, liver-directed therapy has made remarkable strides, with a number of clinical trials currently planned and ongoing in hemophilia A and B, as well as other liver disorders. This review focuses on liver-directed AAV gene therapy, including historic context, current challenges, and future developments.
Get full access to this article
View all access options for this article.
References
1.
MountJD, HerzogRW, TillsonDM, et al.Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood, 2002; 99:2670–2676.
2.
SnyderRO, MiaoC, MeuseL, et al.Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med, 1999; 5:64–70.
3.
WangL, NicholsTC, ReadMS, et al.Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther, 2000; 1:154–158.
4.
JiangH, LillicrapD, Patarroyo-WhiteS, et al.Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood, 2006; 108:107–115.
5.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
6.
NathwaniAC, ReissUM, TuddenhamEG, et al.Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371:1994–2004.
TortoraGJ, DerricksonBH. The digestive system: liver and gallbladder. In: TortoraGJ, DerricksonBH, eds. Principles of Anatomy and Physiology. Hoboken, NJ: John Wiley & Sons, 2012:990–994.
9.
GissenP, AriasIM. Structural and functional hepatocyte polarity and liver disease. J Hepatol, 2015; 63:1023–1037.
10.
GruppusoPA, SandersJA. Regulation of liver development: implications for liver biology across the lifespan. J Mol Endocrinol, 2016; 56:R115–125.
11.
FagiuoliS, DainaE, D'AntigaL, et al.Monogenic diseases that can be cured by liver transplantation. J Hepatol, 2013; 59:595–612.
12.
AlamS, SoodV. Metabolic liver disease: when to suspect and how to diagnose?. Indian J Pediatr, 2016; 83:1321–1333.
13.
Orphanet.
14.
MacdonaldRA. “Lifespan” of liver cells. Autoradio-graphic study using tritiated thymidine in normal, cirrhotic, and partially hepatectomized rats. Arch Intern Med, 1961; 107:335–343.
15.
TerpstraOT, MaltRA, BucherNL. Negligible role of adrenal hormones in regulation of DNA synthesis in livers of partially hepatectomized rats. Proc Soc Exp Biol Med, 1979; 161:326–331.
JacobsF, GordtsSC, MuthuramuI, et al.The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives. Pharmaceuticals (Basel), 2012; 5:1372–1392.
19.
VollmarB, MengerMD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev, 2009; 89:1269–1339.
20.
GaoG, AlviraMR, SomanathanS, et al.Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A, 2003; 100:6081–6086.
21.
GaoG, VandenbergheLH, AlviraMR, et al.Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol, 2004; 78:6381–6388.
22.
GrishamJW. A morphologic study of deoxyribonucleic acid synthesis and cell proliferation in regenerating rat liver; autoradiography with thymidine-H3. Cancer Res, 1962; 22:842–849.
BickelH, GerrardJ, HickmansEM. Influence of phenylalanine intake on phenylketonuria. Lancet, 1953; 265:812–813.
25.
ChapmanMS, Agbandje-McKennaM. Atomic structure of viral particles. In: KerrJR, CotmoreSF, BloomME, LindenRM, ParrishCR, eds. The Parvoviruses. London: Hodder Arnold, 2006:107–123.
26.
QuW, WangM, WuY, et al.Scalable downstream strategies for purification of recombinant adeno-associated virus vectors in light of the properties. Curr Pharm Biotechnol, 2015; 16:684–695.
27.
BurovaE, IoffeE. Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther, 2005; 12:S5–17.
28.
ClementN, GriegerJC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev, 2016; 3:16002.
29.
BernsKI, GiraudC. Adenovirus and adeno-associated virus as vectors for gene therapy. Ann N Y Acad Sci, 1995; 772:95–104.
30.
DongB, NakaiH, XiaoW. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther, 2010; 18:87–92.
31.
WuZ, YangH, ColosiP. Effect of genome size on AAV vector packaging. Mol Ther, 2010; 18:80–86.
32.
ChamberlainK, RiyadJM, WeberT. Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids. Hum Gene Ther Methods, 2016; 27:1–12.
33.
DongJY, FanPD, FrizzellRA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther, 1996; 7:2101–2112.
34.
GriegerJC, SamulskiRJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol, 2005; 79:9933–9944.
35.
LindP, LarssonK, SpiraJ, et al.Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem, 1995; 232:19–27.
36.
HirataRK, RussellDW. Design and packaging of adeno-associated virus gene targeting vectors. J Virol, 2000; 74:4612–4620.
37.
GaoGP, AlviraMR, WangL, et al.Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A, 2002; 99:11854–11859.
38.
ZincarelliC, SoltysS, RengoG, et al.Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther, 2008; 16:1073–1080.
39.
WangL, WangH, BellP, et al.Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther, 2010; 18:118–125.
40.
VandenbergheLH, XiaoR, LockM, et al.Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther, 2010; 21:1251–1257.
41.
CalcedoR, VandenbergheLH, GaoG, et al.Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis, 2009; 199:381–390.
42.
ZhongL, LiB, MahCS, et al.Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A, 2008; 105:7827–7832.
43.
ChengB, LingC, DaiY, et al.Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther, 2012; 19:375–384.
44.
RauppC, NaumerM, MullerOJ, et al.The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol, 2012; 86:9396–9408.
45.
WarringtonKHJr, GorbatyukOS, HarrisonJK, et al.Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol, 2004; 78:6595–6609.
46.
MunchRC, JanickiH, VolkerI, et al.Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther, 2013; 21:109–118.
47.
GrimmD, LeeJS, WangL, et al.In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol, 2008; 82:5887–5911.
48.
LisowskiL, DaneAP, ChuK, et al.Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014; 506:382–386.
49.
KuriyamaS, YoshikawaM, IshizakaS, et al.A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct Funct, 1991; 16:503–510.
50.
SchiednerG, MorralN, ParksRJ, et al.Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet, 1998; 18:180–183.
51.
DangQ, WalkerD, TaylorS, et al.Structure of the hepatic control region of the human apolipoprotein E/C-I gene locus. J Biol Chem, 1995; 270:22577–22585.
52.
DavidoffAM, GrayJT, NgCY, et al.Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther, 2005; 11:875–888.
53.
HafenrichterDG, WuX, RettingerSD, et al.Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood, 1994; 84:3394–3404.
54.
MiaoCH, OhashiK, PatijnGA, et al.Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther, 2000; 1:522–532.
55.
McIntoshJ, LentingPJ, RosalesC, et al.Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 2013; 121:3335–3344.
56.
NathwaniAC, GrayJT, NgCY, et al.Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006; 107:2653–2661.
57.
HayashiY, MoriY, JanssenOE, et al.Human thyroxine-binding globulin gene: complete sequence and transcriptional regulation. Mol Endocrinol, 1993; 7:1049–1060.
58.
RouetP, RaguenezG, TroncheF, et al.A potent enhancer made of clustered liver-specific elements in the transcription control sequences of human alpha 1-microglobulin/bikunin gene. J Biol Chem, 1992; 267:20765–20773.
59.
WangL, CalcedoR, NicholsTC, et al.Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood, 2005; 105:3079–3086.
60.
WangL, TakabeK, BidlingmaierSM, et al.Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sc U S A, 1999; 96:3906–3910.
61.
VignaE, AmendolaM, BenedicentiF, et al.Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. Mol Ther, 2005; 11:763–775.
62.
ChuahMK, PetrusI, De BleserP, et al.Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. Mol Ther, 2014; 22:1605–1613.
63.
NiemeyerGP, HerzogRW, MountJ, et al.Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood, 2009; 113:797–806.
64.
DominguezE, MaraisT, ChatauretN, et al.Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet, 2011; 20:681–693.
65.
FosterH, SharpPS, AthanasopoulosT, et al.Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther, 2008; 16:1825–1832.
66.
NathwaniAC, TuddenhamEG, RangarajanS, et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
67.
PanedaA, Lopez-FrancoE, KaeppelC, et al.Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther, 2013; 24:1007–1017.
68.
WangL, MorizonoH, LinJ, et al.Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. Mol Genet Metab, 2012; 105:203–211.
HauswirthWW, AlemanTS, KaushalS, et al.Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 2008; 19:979–990.
75.
GriegerJC, SoltysSM, SamulskiRJ. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther, 2016; 24:287–297.
76.
ThomasDL, WangL, NiamkeJ, et al.Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther, 2009; 20:861–870.
77.
ClementN, KnopDR, ByrneBJ. Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther, 2009; 20:796–806.
78.
MartinJ, FrederickA, LuoY, et al.Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Methods, 2013; 24:253–269.
79.
GaoG, LuY, CalcedoR, et al.Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther, 2006; 13:77–87.
80.
NathwaniAC, CochraneM, McIntoshJ, et al.Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther, 2009; 16:60–69.
81.
BellP, WangL, GaoG, et al.Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. Mol Genet Metab, 2011; 104:395–403.
82.
CunninghamSC, DaneAP, SpinoulasA, et al.Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther, 2008; 16:1081–1088.
83.
DaneAP, WowroSJ, CunninghamSC, et al.Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. Gene Ther, 2013; 20:460–464.
84.
AlexanderIE, CunninghamSC, LoganGJ, et al.Potential of AAV vectors in the treatment of metabolic disease. Gene Ther, 2008; 15:831–839.
85.
ColnotS, PerretC. Liver zonation. In: MongaSPS, CaglePT eds. Molecular Pathology of Liver Diseases. New York, NY: Springer US, 2010:7–16.
86.
JiangH, CoutoLB, Patarroyo-WhiteS, et al.Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood, 2006; 108:3321–3328.
87.
MurphySL, LiH, ZhouS, et al.Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Mol Ther, 2008; 16:138–145.
88.
LiH, MurphySL, Giles-DavisW, et al.Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther, 2007; 15:792–800.
89.
WangL, FigueredoJ, CalcedoR, et al.Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther, 2007; 18:185–194.
90.
Basner-TschakarjanE, BijjigaE, MartinoAT. Pre-clinical assessment of immune responses to adeno-associated virus (AAV) vectors. Front Immunol, 2014; 5:28.
91.
LiC, HirschM, DiPrimioN, et al.Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J Virol, 2009; 83:6817–6824.
92.
NguyenDH, Hurtado-ZiolaN, GagneuxP, et al.Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci U S A, 2006; 103:7765–7770.
93.
PastoreL, MorralN, ZhouH, et al.Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther, 1999; 10:1773–1781.
94.
CaoO, DobrzynskiE, WangL, et al.Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood, 2007; 110:1132–1140.
95.
MingozziF, HasbrouckNC, Basner-TschakarjanE, et al.Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 2007; 110:2334–2341.
96.
LimmerA, OhlJ, KurtsC, et al.Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med, 2000; 6:1348–1354.
97.
HorstAK, NeumannK, DiehlL, et al.Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol Immunol, 2016; 13:277–292.
98.
CrispeIN. Hepatic T cells and liver tolerance. Nat Rev Immunol, 2003; 3:51–62.
99.
CrispeIN. Immune tolerance in liver disease. Hepatology, 2014; 60:2109–2117.
100.
MingozziF, LiuYL, DobrzynskiE, et al.Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest, 2003; 111:1347–1356.
101.
LoDucaPA, HoffmanBE, HerzogRW. Hepatic gene transfer as a means of tolerance induction to transgene products. Curr Gene Ther, 2009; 9:104–114.
102.
SunJY, Anand-JawaV, ChatterjeeS, et al.Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther, 2003; 10:964–976.
103.
SackBK, MerchantS, MarkusicDM, et al.Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PloS One, 2012; 7:e37671.
104.
HerzogRW, MountJD, ArrudaVR, et al.Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther, 2001; 4:192–200.
105.
FieldsPA, ArrudaVR, ArmstrongE, et al.Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther, 2001; 4:201–210.
106.
EllinwoodNM, AusseilJ, DesmarisN, et al.Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther, 2011; 19:251–259.
107.
MessingerYH, MendelsohnNJ, RheadW, et al.Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med, 2012; 14:135–142.
108.
JolyMS, MartinRP, Mitra-KaushikS, et al.Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa. J Immunol, 2014; 193:3947–3958.
109.
MoskalenkoM, ChenL, van RoeyM, et al.Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol, 2000; 74:1761–1766.
110.
CalcedoR, WilsonJM. Humoral Immune Response to AAV. Front Immunol, 2013; 4:341.
ChicoineLG, MontgomeryCL, BremerWG, et al.Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther, 2014; 22:338–347.
113.
MingozziF, AnguelaXM, PavaniG, et al.Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 2013; 5:194ra192.
114.
DonsanteA, VoglerC, MuzyczkaN, et al.Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther, 2001; 8:1343–1346.
115.
DonsanteA, MillerDG, LiY, et al.AAV vector integration sites in mouse hepatocellular carcinoma. Science, 2007; 317:477.
116.
ChandlerRJ, LaFaveMC, VarshneyGK, et al.Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest, 2015; 125:870–880.
117.
LukJM, BurchardJ, ZhangC, et al.DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem, 2011; 286:30706–30713.
118.
BellP, MoscioniAD, McCarterRJ, et al.Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther, 2006; 14:34–44.
119.
ZhongL, MalaniN, LiM, et al.Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther, 2013; 24:520–525.
120.
LiH, MalaniN, HamiltonSR, et al.Assessing the potential for AAV vector genotoxicity in a murine model. Blood, 2011; 117:3311–3319.
121.
NaultJC, DattaS, ImbeaudS, et al.Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet, 2015; 47:1187–1193.
122.
BernsKI, ByrneBJ, FlotteTR, et al.Adeno-associated virus type 2 and hepatocellular carcinoma?. Hum Gene Ther, 2015; 26:779–781.
123.
BuningH, SchmidtM. Adeno-associated vector toxicity—to be or not to be?. Mol Ther, 2015; 23:1673–1675.
NaldiniL. Gene therapy returns to centre stage. Nature, 2015; 526:351–360.
126.
Gene Therapy Clinical Trials Worldwide. Provided by The Journal of Gene Medicine, Wiley. www.abedia.com/wiley/ (last accessed December12, 2016).
127.
KaeppelC, BeattieSG, FronzaR, et al.A largely random AAV integration profile after LPLD gene therapy. Nat Med, 2013; 19:889–891.
128.
Gil-FarinaI, FronzaR, KaeppelC, et al.Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther, 2016; 24:1100–1105.
